[{"data":1,"prerenderedAt":27},["ShallowReactive",2],{"$fflKE0lhVJQpY3OH82zy9zpaQXuNDkzFdbhZFwXAwc00":3},{"card":4,"examId":6,"chapterTitle":24,"prev":25,"next":26},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":17,"lectureRef":18,"storyRef":18,"chapterSlug":19,"sectionCode":20,"sectionTitle":21,"clusterSlug":22,"term":18,"sequenceOrder":18,"regionWeight":18,"revisionMark":18,"isActive":23},"ch2-120","touhan","非臨床試験で求められる、毒性反応が発現しない最大の投与量を何というか？",0,[10,11,12,13],"無毒性量（NOAEL）","最小致死量（MLD）","50%致死量（LD50）","治療係数","four","無毒性量（NOAEL: No Observed Adverse Effect Level）は動物実験で毒性反応が認められない最大の投与量。","新規医薬品の安全性評価ではまず動物を用いた非臨床試験で無毒性量を求め、それをもとに安全係数を考慮してヒトへの投与量を設定する。NOAELに基づく安全域の設定は薬物の安全性評価の基本的な考え方である。LD50（50%致死量）は薬物の毒性の強さの指標。","NOAEL＝毒性が「出ない」最大量。LD50＝実験動物の半数が死亡する量。両者は全く異なる概念。",null,"chapter-2","2-II","薬が働く仕組み","yakuri-kiko",true,"第2章 人体の働きと医薬品","ch2-119","ch2-121",1784619073755]